118 related articles for article (PubMed ID: 35081321)
1. Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013-2021).
Yu X; Li S; Zhu X; Kong Y
Expert Opin Ther Pat; 2022 Feb; 32(2):153-170. PubMed ID: 35081321
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold.
Liu S; Yuan D; Li S; Xie R; Kong Y; Zhu X
Eur J Med Chem; 2021 Dec; 225():113764. PubMed ID: 34391031
[TBL] [Abstract][Full Text] [Related]
4. Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy.
Rwibasira Rudinga G; Khan GJ; Kong Y
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29443899
[TBL] [Abstract][Full Text] [Related]
5. Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog.
Lin YC; Ko YC; Hung SC; Lin YT; Lee JH; Tsai JY; Kung PH; Tsai MC; Chen YF; Wu CC
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):694-703. PubMed ID: 30727756
[TBL] [Abstract][Full Text] [Related]
6. Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
Liu S; Li S; Yuan D; Wang E; Xie R; Zhang W; Kong Y; Zhu X
Eur J Med Chem; 2021 Jan; 209():112893. PubMed ID: 33049608
[TBL] [Abstract][Full Text] [Related]
7. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
Wong PC; Seiffert D; Bird JE; Watson CA; Bostwick JS; Giancarli M; Allegretto N; Hua J; Harden D; Guay J; Callejo M; Miller MM; Lawrence RM; Banville J; Guy J; Maxwell BD; Priestley ES; Marinier A; Wexler RR; Bouvier M; Gordon DA; Schumacher WA; Yang J
Sci Transl Med; 2017 Jan; 9(371):. PubMed ID: 28053157
[TBL] [Abstract][Full Text] [Related]
8. Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?
Li S; Tarlac V; Hamilton JR
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717963
[TBL] [Abstract][Full Text] [Related]
9. Genetic deletion of platelet PAR4 results in reduced thrombosis and impaired hemostatic plug stability.
Lee RH; Kawano T; Grover SP; Bharathi V; Martinez D; Cowley DO; Mackman N; Bergmeier W; Antoniak S
J Thromb Haemost; 2022 Feb; 20(2):422-433. PubMed ID: 34689407
[TBL] [Abstract][Full Text] [Related]
10. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.
Covic L; Gresser AL; Kuliopulos A
Biochemistry; 2000 May; 39(18):5458-67. PubMed ID: 10820018
[TBL] [Abstract][Full Text] [Related]
11. An optimized agonist peptide of protease-activated receptor 4 and its use in a validated platelet-aggregation assay.
Yang J; Mapelli C; Wang Z; Sum CS; Hua J; Lawrence RM; Ni Y; Seiffert DA
Platelets; 2022 Oct; 33(7):979-986. PubMed ID: 35343875
[TBL] [Abstract][Full Text] [Related]
12. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
[TBL] [Abstract][Full Text] [Related]
13. Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking.
Norman JE; Cunningham MR; Jones ML; Walker ME; Westbury SK; Sessions RB; Mundell SJ; Mumford AD
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):952-60. PubMed ID: 26966273
[TBL] [Abstract][Full Text] [Related]
14. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation.
Wilson SJ; Ismat FA; Wang Z; Cerra M; Narayan H; Raftis J; Gray TJ; Connell S; Garonzik S; Ma X; Yang J; Newby DE
Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):448-456. PubMed ID: 29269513
[TBL] [Abstract][Full Text] [Related]
15. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.
Kahn ML; Nakanishi-Matsui M; Shapiro MJ; Ishihara H; Coughlin SR
J Clin Invest; 1999 Mar; 103(6):879-87. PubMed ID: 10079109
[TBL] [Abstract][Full Text] [Related]
16. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
[TBL] [Abstract][Full Text] [Related]
17. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 7, 4'-dimethoxy-3-hydroxyflavone as a protease-activated receptor 4 antagonist with antithrombotic activity and less bleeding tendency in mice.
Lin YT; Li Y; Hsu HC; Tsai JY; Lee JH; Tai CJ; Wu MJ; Wu CC
Biochem Pharmacol; 2022 Aug; 202():115152. PubMed ID: 35752281
[TBL] [Abstract][Full Text] [Related]
19. Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis.
Mumaw MM; de la Fuente M; Noble DN; Nieman MT
J Thromb Haemost; 2014 Aug; 12(8):1331-41. PubMed ID: 24888424
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4.
Priestley ES; Banville J; Deon D; Dubé L; Gagnon M; Guy J; Lapointe P; Lavallée JF; Martel A; Plamondon S; Rémillard R; Ruediger E; Tremblay F; Posy SL; Guarino VR; Richter JM; Li J; Gupta A; Vetrichelvan M; Balapragalathan TJ; Mathur A; Hua J; Callejo M; Guay J; Sum CS; Cvijic ME; Watson C; Wong P; Yang J; Bouvier M; Gordon DA; Wexler RR; Marinier A
J Med Chem; 2022 Jul; 65(13):8843-8854. PubMed ID: 35729784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
